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Transient depletion of RUNX1/RUNX1T1 by RNA interference 
delays tumour formation in vivo 
To the Editor 
The chromosomal translocation t(8;21)(q22;q22) occurs in about 10% 
of all cases of acute myeloid leukaemia (AML) and is one of the most frequent 
chromosomal abnormalities found in AML (1). This translocation generates 
the RUNX1/RUNX1T1 (AML1/MTG8, AML1/ETO) fusion gene, which by itself 
is not sufficient for full leukaemic transformation, but which supports human 
haematopoietic stem/progenitor cell self-renewal in vivo as well as leukaemic 
proliferation and clonogenicity ex vivo (2-4). Generation of RUNX1/RUNX1T1 
may not only be an initiating event in leukaemogenesis, but might also 
become a leukaemia-specific target for therapeutic approaches. However, its 
role in leukaemic persistence in vivo and, in particular, its significance for 
leukaemic stem cells has not been established yet. 
One prerequisite for studying possible functions of RUNX1/RUNX1T1 
in maintaining leukaemia in vivo and the development of therapies targeting 
this genetic lesion is the availability of suitable animal model systems. Several 
transgenic and knock-in mouse models have been developed to study 
RUNX1/RUNX1T1-driven leukaemogenesis in murine haematopoietic cells 
(5). However, in vivo studies of RUNX1/RUNX1T1 in the human leukaemic 
background are currently limited due to a lack of suitable xenotransplantation 
models, as t(8;21)-positive leukaemic cells including established cell lines do 
not or only rarely engraft in Nod/Scid mouse strains (6).  
The Rag2-/-γc-/- mouse strain which lacks B, T and NK cells represents 
an interesting alternative to Scid-based mouse strains. For instance, 
intrahepatic injection of CD34+ human cord blood cells into newborn BALB/c 
Rag2-/-γc-/- mice leads to the development of an adaptive immune system (7). 
We tested this immunodeficient mouse strain in combination with the t(8;21)-
positive AML cell line Kasumi-1 in order to establish a xenotransplantation 
model for t(8;21)-associated AML. Sublethally irradiated newborn mice 
received an intraperitoneal injection of 106 Kasumi-1 cells. Within 53 to 55 
days, transplanted mice developed swollen abdomen or showed other signs 
of tumour formation. Postmortem examination revealed mainly solid tumours 
of 1 cm - 1.5 cm in diameter (Figure 1a) located intraperitoneally. Tumour 
histology and flow cytometry analyses revealed that the tumours consisted 
almost exclusively of human myeloid CD45+ CD34+ CD33+ cells, which is 
concordant with the immunophenotype of Kasumi-1 cells (Figure 1b, c, and 
data not shown). Notably, such extramedullary myeloid tumours (granulocytic 
sarcomas, chloromas) are found in some 20% of all t(8;21) AML cases (8). In 
less than half of the animals we observed infiltration of the spleen by 
leukaemic cells, but neither bone marrow nor liver infiltration (Figure 1c). 
Consistent with this, RUNX1/RUNX1T1 protein was strongly expressed in 
tumours, occasionally and weakly in spleen and never in liver (Figure 1d). 
We recently analysed the significance of RUNX1/RUNX1T1 for 
leukaemic proliferation and clonogenicity using short interfering RNAs 
(siRNAs). A single siRNA treatment caused a transient reduction in fusion 
protein levels lasting 5 to 7 days. siRNA-mediated RUNX1/RUNX1T1 
depletion restored myeloid differentiation capacity, inhibited proliferation and 
severely impaired leukaemic clonogenicity in vitro (3, 4). However, these 
experiments did not address the in vivo significance of this leukaemic fusion 
protein in human leukaemic cells. To examine the consequences of a 
transient RUNX1/RUNX1T1 depletion on leukaemic engraftment and tumour 
formation, we used the Rag2-/-γc-/- transplantation system. We electroporated 
Kasumi-1 cells either in the absence of any siRNA (“Mock”), with siRNA 
targeting the RUNX1/RUNX1T1 fusion site (“siAGF1”) or with a mismatch 
control siRNA (“siAGF6”) as described previously (3). siRNA-mediated 
RUNX1/RUNX1T1 suppression was examined by western blotting and 
functionally analysed by colony formation assays (4). In comparison to mock 
and mismatch siRNA-treated cells, siAGF1-treated cells showed at least a 
threefold decrease in fusion protein and a sixfold decrease in colony forming 
cells in vitro (Figures 2a, b). One day after siRNA treatment, cells were either 
transplanted or stored in liquid nitrogen till transplantation. Transplantations 
were performed by intraperitoneally injecting 106 electroporated cells into 
sublethally irradiated newborn mice. Total group sizes were 12 animals for the 
mock group, 11 animals for the active siRNA group and 10 animals for the 
mismatch control siRNA group. Transplantation of mock- or mismatch siRNA-
treated cells resulted in tumour formation in all transplanted animals with a 
median survival of 50 days (Figure 2c). In contrast, pre-treatment with the 
active RUNX1/RUNX1T1 siRNA siAGF1 resulted in an extended median 
survival of 73 days (p < 0.02). Notably, 3 animals of the active siRNA group 
examined 71 days post transplantation showed no signs of tumour formation 
in histological analyses. In a second set of experiments, 2.5 x 105 cells were 
transplanted 8 hours after siRNA electroporation into non-irradiated mice. In 
this experiment, groups of 8 and 7 animals were transplanted with active and 
mismatch siRNA-pre-treated cells. This setting resulted in a median survival 
of 64 and 90 days for the mismatch siRNA and the active siRNA group, 
respectively. Again, the difference in median survival was statistically 
significant (p < 0.02) suggesting that siRNA-mediated transient reduction of 
RUNX1/RUNX1T1 causes a substantial decrease in cancer-initiating cells.  
In summary, we show that already a transient siRNA-mediated 
depletion of RUNX1/RUNX1T1 causes a significant increase in median 
survival in a xenotransplantation model. These findings suggest that 
RUNX1/RUNX1T1 siRNAs compromises the engraftment and/or self-renewal 
capacities of t(8;21) leukaemia-initiating cells. Future studies will show, 
whether RNAi-mediated RUNX1/RUNX1T1 suppression during and after 
leukaemic engraftment may stop or even reverse tumour formation, 
consequently paving the way for developing therapeutic approaches directly 
targeting this leukaemic fusion protein. 
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Figure legends 
Figure 1: Analysis of Rag2-/-γc-/- mice xenotransplanted with t(8;21) AML cells. 
Newborn mice were transplanted with t(8;21)-positive Kasumi-1 cells. Animals 
had to be humanely killed within 50-70 d because of tumour burden. (A) 
Tumour excised from the abdominal cavity of an animal transplanted with 106 
cells. (B) Tumour histology. The animal was transplanted with 2.5 x 105 cells 
pre-treated with the mismatch control siRNA siAGF6. The tumour was stained 
with Hematoxylin/Eosin. The original magnification was 20x. (C) Flow 
cytometry analysis of tumour-,spleen- and bone marrow-derived cells. 
Examples for infiltrated (top right) and non-infiltrated spleens (bottom right) 
are shown. The red curves show cells stained with α-human CD45 antibody, 
the blue curves show isotype controls.The top right panel shows an example 
for a spleen with leukaemic infiltration. (D) Immunoblot analysis for 
RUNX1/RUNX1T1 expression. Tissues are indicated at the top, detected 
proteins on the right and length marker sizes on the left. Mouse 1 and 2 were 
transplanted animals; control indicates a non-transplanted control animal. 
Kasumi-1 cells served as positive control. RUNX1/RUNX1T1 was detected 
with an anti-AML1 antibody as described (4). Tubulin (TUB) served as a 
loading control. Note the RUNX1/RUNX1T1 signal in spleen lysate from 
animal 2 indicating weak leukaemic spleen infiltration. 
 
Figure 2: siRNA-mediated RUNX1/RUNX1T1 suppression decreases 
leukaemic clonogenicity and extends median survival. 
Kasumi-1 cells were electroporated with the indicated siRNAs as described 
previously (4). Cells were examined for RUNX1/RUNX1T1 protein levels and 
colony formation in vitro, and transplanted into newborn Rag2-/-γc-/- mice.  (A) 
Immunoblot for RUNX1/RUNX1T1 expression in siRNA-treated Kasumi-1 
cells. siRNA treatments are indicated at the top, detected proteins on the right 
and length marker sizes on the left. RUNX1/RUNX1T1 and RUNX1 were 
detected with an anti-AML1 antibody as described (4). Tubulin (TUB) served 
as a loading control. (B) Colony formation of siRNA-treated Kasumi-1 cells. 
Colony formation assays were performed as described (4). CFC, colony 
forming cells. Error bars indicate standard deviations. (C) Survival curves of 
Rag2-/-γc-/- mice transplanted with 106 siRNA-treated Kasumi-1 cells. Pre-
treatment with the RUNX1/RUNX1T1 siRNA siAGF1 extended median 
survival significantly compared to mock or control siRNA siAGF6 pre-
treatment (p < 0.02 according to log-rank test). In each treatment arm, at least 
10 mice were transplanted. (D) Survival curves of Rag2-/-γc-/- mice 
transplanted with 2.5 x 105 siRNA-treated Kasumi-1 cells. Pre-treatment with 
the RUNX1/RUNX1T1 siRNA siAGF1 extended median survival significantly 
compared to control siRNA siAGF6 pre-treatment (p < 0.02 according to log-
rank test). In each treatment arm, at least 7 mice were transplanted. 
 
 
